• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

噻吗洛尔从表面改性固体脂质纳米粒通过生物工程化人角膜的缓释与渗透。

Sustained release and permeation of timolol from surface-modified solid lipid nanoparticles through bioengineered human cornea.

作者信息

Attama A A, Reichl S, Müller-Goymann C C

机构信息

Institut für Pharmazeutische Technologie, Technische Universität Carolo-Wilhelmina zu Braunschweig, Braunschweig, Germany.

出版信息

Curr Eye Res. 2009 Aug;34(8):698-705. doi: 10.1080/02713680903017500.

DOI:10.1080/02713680903017500
PMID:19899997
Abstract

PURPOSE

The aim of the study was to formulate and evaluate surface-modified solid lipid nanoparticles sustained delivery system of timolol hydrogen maleate, a prototype ocular drug using a human cornea construct.

MATERIALS AND METHODS

Surface-modified solid lipid nanoparticles containing timolol with and without phospholipid were formulated by melt emulsification with high-pressure homogenization and characterized by particle size, wide-angle X-ray diffraction, encapsulation efficiency, and in vitro drug release. Drug transport studies through cornea bioengineered from human donor cornea cells were carried out using a modified Franz diffusion cell and drug concentration analyzed by high-performance liquid chromatography.

RESULTS

Results show that surface-modified solid lipid nanoparticles possessed very small particles (42.9 +/- 0.3 nm, 47.2 +/- 0.3 nm, 42.7 +/- 0.7 nm, and 37.7 +/- 0.3 nm, respectively for SM-SLN 1, SM-SLN 2, SM-SLN 3, and SM-SLN 4) with low polydispersity indices, increased encapsulation efficiency (> 44%), and sustained in vitro release compared with unmodified lipid nanoparticles whose particles were greater than 160 nm. Permeation of timolol hydrogen maleate from the surface-modified lipid nanoparticles across the cornea construct was sustained compared with timolol hydrogen maleate solution in distilled water.

CONCLUSIONS

Surface-modified solid lipid nanoparticles could provide an efficient way of improving ocular bioavailability of timolol hydrogen maleate.

摘要

目的

本研究旨在制备并评估马来酸噻吗洛尔的表面修饰固体脂质纳米粒缓释给药系统,马来酸噻吗洛尔是一种典型的眼用药物,采用人角膜构建体进行研究。

材料与方法

采用熔融乳化结合高压均质法制备含和不含磷脂的马来酸噻吗洛尔表面修饰固体脂质纳米粒,并通过粒径、广角X射线衍射、包封率和体外药物释放进行表征。使用改良的Franz扩散池进行药物透过人供体角膜细胞构建的角膜的转运研究,并通过高效液相色谱分析药物浓度。

结果

结果表明,表面修饰的固体脂质纳米粒具有非常小的粒径(SM-SLN 1、SM-SLN 2、SM-SLN 3和SM-SLN 4的粒径分别为42.9±0.3nm、47.2±0.3nm、42.7±0.7nm和37.7±0.3nm),多分散指数低,包封率提高(>44%),与粒径大于160nm的未修饰脂质纳米粒相比,体外释放具有缓释特性。与马来酸噻吗洛尔在蒸馏水中的溶液相比,马来酸噻吗洛尔从表面修饰的脂质纳米粒透过角膜构建体的渗透具有缓释特性。

结论

表面修饰的固体脂质纳米粒可为提高马来酸噻吗洛尔的眼内生物利用度提供一种有效方法。

相似文献

1
Sustained release and permeation of timolol from surface-modified solid lipid nanoparticles through bioengineered human cornea.噻吗洛尔从表面改性固体脂质纳米粒通过生物工程化人角膜的缓释与渗透。
Curr Eye Res. 2009 Aug;34(8):698-705. doi: 10.1080/02713680903017500.
2
Nanogel-based natural polymers as smart carriers for the controlled delivery of Timolol Maleate through the cornea for glaucoma.基于纳米凝胶的天然聚合物作为智能载体,通过角膜控制马来酸噻吗洛尔的递送,用于治疗青光眼。
Int J Biol Macromol. 2018 Apr 1;109:955-962. doi: 10.1016/j.ijbiomac.2017.11.090. Epub 2017 Nov 14.
3
Solid lipid nanodispersions containing mixed lipid core and a polar heterolipid: characterization.含有混合脂质核心和极性异质脂质的固体脂质纳米分散体:表征
Eur J Pharm Biopharm. 2007 Aug;67(1):48-57. doi: 10.1016/j.ejpb.2006.12.004. Epub 2006 Dec 16.
4
Physicochemical and pharmacological investigation of water/oil microemulsion of non-selective beta blocker for treatment of glaucoma.水/油型微乳非选择性β受体阻滞剂滴眼剂的理化性质及药效学研究。
Curr Eye Res. 2014 Feb;39(2):155-63. doi: 10.3109/02713683.2013.833630. Epub 2013 Sep 27.
5
Ocular Cubosome Drug Delivery System for Timolol Maleate: Preparation, Characterization, Cytotoxicity, Ex Vivo, and In Vivo Evaluation.马来酸噻吗洛尔眼用 Cubosome 给药系统的制备、表征、细胞毒性、离体和体内评价。
AAPS PharmSciTech. 2017 Nov;18(8):2919-2926. doi: 10.1208/s12249-017-0763-8. Epub 2017 Apr 20.
6
Diclofenac sodium delivery to the eye: in vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct.双氯芬酸钠眼部给药:使用人角膜构建体对新型固体脂质纳米粒制剂进行体外评价
Int J Pharm. 2008 May 1;355(1-2):307-13. doi: 10.1016/j.ijpharm.2007.12.007. Epub 2007 Dec 17.
7
Development of Timolol Maleate Loaded Chitosan Nanoparticles For Improved Ocular Delivery.用于改善眼部给药的马来酸噻吗洛尔壳聚糖纳米粒的研制
Pharm Nanotechnol. 2017;5(4):310-316. doi: 10.2174/2211738505666170828101559.
8
Development of Timolol-Loaded Galactosylated Chitosan Nanoparticles and Evaluation of Their Potential for Ocular Drug Delivery.载噻吗洛尔的半乳糖基化壳聚糖纳米粒的研制及其眼部给药潜力评估
AAPS PharmSciTech. 2017 May;18(4):997-1008. doi: 10.1208/s12249-016-0669-x. Epub 2017 Jan 18.
9
Fabrication and Characterization of Timolol Maleate and Brinzolamide Loaded Nanostructured Lipid Carrier System for Ocular Drug Delivery.用于眼部给药的马来酸噻吗洛尔和布林佐胺负载纳米结构脂质载体系统的制备与表征
Curr Drug Deliv. 2018;15(6):829-839. doi: 10.2174/1566523218666171129205626.
10
Temperature sensitive contact lenses for triggered ophthalmic drug delivery.温度敏感型接触镜用于触发式眼科药物递送。
Biomaterials. 2012 Mar;33(7):2289-300. doi: 10.1016/j.biomaterials.2011.10.076. Epub 2011 Dec 17.

引用本文的文献

1
Research progress of nano delivery systems for intraocular pressure lowering drugs.降眼压药物纳米递送系统的研究进展
Heliyon. 2024 Jun 12;10(12):e32602. doi: 10.1016/j.heliyon.2024.e32602. eCollection 2024 Jun 30.
2
Drug delivery methods based on nanotechnology for the treatment of eye diseases.基于纳米技术的治疗眼部疾病的药物递送方法。
Ann Med Surg (Lond). 2023 Oct 17;85(12):6029-6040. doi: 10.1097/MS9.0000000000001399. eCollection 2023 Dec.
3
Tioconazole-Loaded Transethosomal Gel Using Box-Behnken Design for Topical Applications: In Vitro, In Vivo, and Molecular Docking Approaches.
采用Box-Behnken设计的载有噻康唑的转质体凝胶用于局部应用:体外、体内及分子对接方法
Gels. 2023 Sep 21;9(9):767. doi: 10.3390/gels9090767.
4
Preparation of a Sunitinib loaded microemulsion for ocular delivery and evaluation for the treatment of corneal neovascularization and .用于眼部给药的载有舒尼替尼的微乳剂的制备及其治疗角膜新生血管的评估
Front Pharmacol. 2023 Jul 11;14:1157084. doi: 10.3389/fphar.2023.1157084. eCollection 2023.
5
Formulation and In-Vitro/Ex-Vivo Characterization of Pregelled Hybrid Alginate-Chitosan Microparticles for Ocular Delivery of Ketorolac Tromethamine.用于酮咯酸氨丁三醇眼部给药的预胶凝海藻酸盐-壳聚糖杂化微粒的制剂及其体外/离体表征
Polymers (Basel). 2023 Jun 21;15(13):2773. doi: 10.3390/polym15132773.
6
Nanocarriers for the Delivery of Neuroprotective Agents in the Treatment of Ocular Neurodegenerative Diseases.用于递送神经保护剂治疗眼部神经退行性疾病的纳米载体
Pharmaceutics. 2023 Mar 3;15(3):837. doi: 10.3390/pharmaceutics15030837.
7
Nanoparticles for the treatment of glaucoma-associated neuroinflammation.用于治疗青光眼相关神经炎症的纳米颗粒。
Eye Vis (Lond). 2022 Jul 2;9(1):26. doi: 10.1186/s40662-022-00298-y.
8
Development and Optimization of Hyaluronic Acid-Poloxamer In-Situ Gel Loaded with Voriconazole Cubosomes for Enhancement of Activity against Ocular Fungal Infection.载伏立康唑立方液晶纳米粒的透明质酸-泊洛沙姆原位凝胶的研制与优化以增强抗眼部真菌感染活性
Gels. 2022 Apr 14;8(4):241. doi: 10.3390/gels8040241.
9
Lipid Nanoparticles for the Posterior Eye Segment.用于眼后节的脂质纳米颗粒。
Pharmaceutics. 2021 Dec 31;14(1):90. doi: 10.3390/pharmaceutics14010090.
10
Novel Drug Delivery Systems Fighting Glaucoma: Formulation Obstacles and Solutions.对抗青光眼的新型药物递送系统:制剂障碍与解决方案
Pharmaceutics. 2020 Dec 26;13(1):28. doi: 10.3390/pharmaceutics13010028.